NYSE

Veradermics, Incorporated (MANE)

343 Thanks from members

Veradermics, Incorporated (NYSE: MANE) exhibits highly favorable market and clinical sentiment driven by positive Phase 2/3 trials for its lead oral hair loss candidate, VDPHL01, backed by robust liquidity following an upsized IPO.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →